Theses›Healthcare & bio›Light-controlled therapeutics

Light-controlled therapeutics

Does light become a paid therapeutic control layer beyond dermatology once the first optogenetic, photoimmunotherapy and endoscopic light-drug approvals arrive (2027-2029)?

  • Early
  • $15B by 2035

The call, a draftThe approvals side is ahead: an optogenetic eye therapy, a bladder drug lit through a scope and a near-infrared tumour treatment are all near a decision. Light still only reaches about a centimetre into tissue, so the window is early.

D1D2D3D4R1R2R3C1C2C3foragainst D1D2D3D4R1R2R3C1C2C3foragainst
Fig. 1The balance. Drivers and catalysts against restraints, each block sized by its weight; catalysts hang dashed because they have not happened yet, sized by their odds. It tips toward the drivers.
  1. D1Nanoscope's optogenetic gene therapy MOGENRY had its FDA licence application accepted in Sep 2026, with a decision expected in 2027.
  2. D2Theralase plans to file Ruvidar for BCG-unresponsive bladder cancer from 3Q 2026, with light delivered through a cystoscope in a fully enrolled 90-patient trial.
  3. D3Rakuten Medical's near-infrared photoimmunotherapy is already approved in Japan as Akalux, with a US filing targeted for 2028.
  4. D4The 2026 Nobel prize for optogenetics and GenSight's NEJM paper of 7 Oct 2026 put the field in front of buyers and acquirers.
  5. R1Useful light reaches about 1mm into tissue at blue wavelengths and about 1cm at red, so the brain and heart need an implant or a converter particle that nobody has shown in a mammal.
  6. R2Red and near-infrared photoswitches have only worked in tadpoles and brain slices so far, with no mammal result.
  7. R3GenSight has about €0.7M of cash and a going-concern warning, and RetroSense's asset failed in Phase 1 under AbbVie.
  8. C1FDA approves an optogenetic gene therapy for retinitis pigmentosa, MOGENRY or another.31 Dec 2027
  9. C2Health Canada or FDA approves Ruvidar for BCG-unresponsive bladder cancer with carcinoma in situ.31 Dec 2027
  10. C3A randomised optogenetic trial in geographic atrophy is registered, with Nanoscope the named candidate.30 Jun 2027
What would prove itdated tests, open and resolved
2027202820292030203120322033today12345678predictionswatch 2027202820292030203120322033today12345678predictionswatch
Fig. 2Each ring is a dated test: dashed while open, struck through when overdue, ticked or crossed once resolved.
  1. 1An optogenetic gene therapy starts a registered randomised trial in geographic atrophy by 30 Jun 2027.Jun 2027 · open
  2. 2FDA approves an optogenetic gene therapy for retinitis pigmentosa (MOGENRY or another) by 31 Dec 2027.Dec 2027 · open
  3. 3Health Canada or FDA approves Ruvidar (TLD-1433) for BCG-unresponsive NMIBC with carcinoma in situ by 31 Dec 2027.Dec 2027 · open
  4. 4The FDA decision on MOGENRY and the price and reimbursement it gets.Dec 2027 · open
  5. 5Theralase completes its rolling filing for Ruvidar, planned by 31 Mar 2027.Dec 2027 · open
  6. 6Rakuten Medical's Phase 3 ASP-1929-381 reports a positive primary endpoint by 31 Dec 2028.Dec 2028 · open
  7. 7Rakuten Medical's Phase 3 ASP-1929 readout in first-line recurrent head and neck cancer, due by end-2028.Dec 2028 · open
  8. 8A red or near-infrared photoswitch or implanted light source working in a mammal at 3mm or deeper.Dec 2032 · open
Expressionslisted, private, technologies
Private · 36 private companies, 2 of them in China.

Ondine Biomedical · Coave Therapeutics · Nanoscope Therapeutics · Ray Therapeutics · Rakuten Medical · OptoGenTech · Modulight · RhyGaze · Bionic Sight · Restore Vision · Modulight Biotherapeutics · UgeneX Therapeutics · AviadoBio · Jianda Jiuzhou · Zhongmou Therapeutics · Circuit Therapeutics · RetroSense Therapeutics · Vedere Bio · Arctos Medical · SpectraCure · Steba Biotech · ImPact Biotech · Lumox · GenLumina · LightOx · Lumobiotics · Light Switch Bio · Bayon Therapeutics · Photoswitch Therapeutics · Lumeda · Science Corp · Pixium Vision · NeuroLux · Kendall Research Systems · Medlight · LumiThera

1 more private company tracked, not shown

Technologies
What changedthe record, newest first
  • 12 Oct 2026Light-controlled therapy is two or three years from its first US approvals outside the skin, and all of them are in places light already reaches: the eye, the bladder through a scope, a tumour lit by a laser.
  • 12 Oct 2026The money in light-controlled therapy is betting on geographic atrophy and an IPO window after the first optogenetic approval in 2027, not on light as a category.